Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ciba-Geigy/Gipharmex Deursil

Executive Summary

Gallstone dissolver, approved Dec. 31, will be marketed in U.S. by Ciba-Geigy under licensing agreement with ltalian firm Gipharmex S.p.A. Ciba-Geigy said it assumes on Jan. 9 all rights to Deursil's approved NDA. Ciba-Geigy plans to launch Deursil 150 mg and 300 mg caps in the latter part of 1988. Deursil is indicated for "patients with radiolucent,-non-calcified, gallbladder stones" who carry high surgical risk or who refuse surgery.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel